Scinai Immunotherapeutics (SCNI) Cash & Current Investments (2015 - 2026)

Scinai Immunotherapeutics has reported Cash & Current Investments for 12 years, with the latest figure at $3.1 billion in Q1 2026.

• Quarterly Cash & Current Investments rose 270918.28% year-over-year to $3.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 270918.28% YoY) and the FY2025 annual result came in at $151.7 million, up 7139.19% from the prior year.
• Cash & Current Investments climbed to $3.1 billion in Q1 2026 per SCNI's latest filing, from $151.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $3.1 billion in Q1 2026 and troughed at $1.1 million in Q1 2025.
• A 5-year average of $211.4 million and a median of $10.1 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments sank 77.69% in 2025, then surged 270918.28% in 2026.
• Over 5 years, Cash & Current Investments stood at $14.2 million in 2022, then slumped by 64.76% to $5.0 million in 2023, then sank by 58.18% to $2.1 million in 2024, then surged by 7139.19% to $151.7 million in 2025, then jumped by 1953.26% to $3.1 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.1 billion, $151.7 million, and $1.3 million for Q1 2026, Q4 2025, and Q2 2025 respectively.